New anxiety pill shows promise in Late-Stage trial
NCT ID NCT06741228
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tests whether an oral medication called MM120 can reduce anxiety symptoms in adults with generalized anxiety disorder. About 214 participants will receive either MM120 or a placebo for 12 weeks, followed by a 40-week period where everyone can receive MM120. The main goal is to see if MM120 lowers anxiety scores on a standard rating scale.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED ANXIETY DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Adams Clinical Boston
Boston, Massachusetts, 02116, United States
-
Adams Clinical Bronx
The Bronx, New York, 10461, United States
-
Adams Clinical Dallas
DeSoto, Texas, 75115, United States
-
Adams Clinical Harlem
New York, New York, 10029, United States
-
Adams Clinical Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Adams Clinical Watertown
Watertown, Massachusetts, 02472, United States
-
Atlanta Center for Medical Research
Atlanta, Georgia, 30331, United States
-
Austin Clinical Trial Partners
Austin, Texas, 78737, United States
-
BioBehavioral Research of Austin
Austin, Texas, 78759, United States
-
Cedar Clinical Research
Draper, Utah, 84020, United States
-
CenExel iResearch, LLC
Savannah, Georgia, 31405, United States
-
Cleveland Clinic Lutheran Hospital
Cleveland, Ohio, 44113, United States
-
Clinical Neuroscience Solutions Inc.
Jacksonville, Florida, 32256, United States
-
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee, 38119, United States
-
Coastal Carolina Research Center
North Charleston, South Carolina, 29405, United States
-
FutureSearch Trials of Dallas, LLC
Dallas, Texas, 75231, United States
-
Hassman Research Institute
Marlton, New Jersey, 08053, United States
-
Inner Space Research
Orem, Utah, 84058, United States
-
Kadima Neuropsychiatry Institute
La Jolla, California, 92037, United States
-
Lighthouse Psychiatry
Gilbert, Arizona, 85234, United States
-
Memory Clinic Inc.
Bennington, Vermont, 05201, United States
-
Mountain View
Denver, Colorado, 80209, United States
-
New York State Psychiatric Institute (NYSPI)
New York, New York, 10032, United States
-
Psychedelic Science Institute
Santa Monica, California, 90404, United States
-
Scottsdale Research Institute
Scottsdale, Arizona, 85022, United States
-
Scranton Medical Institute
Moosic, Pennsylvania, 18507, United States
-
Seattle Neuropsychiatric Treatment Center
Seattle, Washington, 98104, United States
-
Segal Trials
Lauderhill, Florida, 33319, United States
-
Spectrum Neuroscience and Treatment Institute
New York, New York, 10021, United States
-
Summit Headlands LLC
Portland, Oregon, 97210, United States
-
UCSF Department of Neurology
San Francisco, California, 94158, United States
-
University of Texas at Austin
Austin, Texas, 78712, United States
-
Uptown Research Institute
Chicago, Illinois, 60640, United States
-
iResearch Atlanta
Decatur, Georgia, 30030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill quiet the mind? a large trial puts it to the test
- Can a unified therapy tame both addiction and emotional disorders?
- Can learning Self-Compassion quiet anxiety and depression?
- A common antidepressant may tame anxiety in kids with autism and ADHD — a trial puts it to the test
- Can money worries trigger depression in students? a study digs deep
- Could a group therapy tackle both depression and anxiety in teens?